A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti‐inflammatory effects in lipopolysaccharide‐induced sepsis in mice
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and purpose: Escherichia coli Nissle 1917 is a probiotic strain used in the treatment of intestinal immune diseases, including ulcerative colitis. The aim of the present study was to test if this probiotic bacterium can also show systemic immunomodulatory properties after oral administration. Experimental approach: The probiotic strain was administered to rats or mice for 2 weeks before its assay in two experimental models of altered immune response, the trinitrobenzenesulphonic acid (TNBS) model of rat colitis, localized in the colon, and the lipopolysaccharide (LPS) model of systemic septic shock in mice. Inflammatory status was evaluated both macroscopically and biochemically after 1 week in the TNBS model or after 24 h in the LPS shock model. In addition, splenocytes were obtained from mice and stimulated, ex vivo, with concanavalin A or LPS to activate T or B cells, respectively, and cytokine production (IL‐2, IL‐5 and IL‐10) by T cells and IgG secretion by B cells measured. Key results: E. coli Nissle 1917 was anti‐inflammatory in both models of altered immune response. This included a reduction in the pro‐inflammatory cytokine tumour necrosis factor‐α both in the intestine from colitic rats, and in plasma and lungs in mice treated with LPS. The systemic beneficial effect was associated with inhibited production of the T cell cytokines and by down‐regulation of IgG release from splenocyte‐derived B cells. Conclusions and implications: The anti‐inflammatory effects of E. coli Nissle 1917 given orally were not restricted to the gastrointestinal tract.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059 · cited 4×
“The exact mechanisms involved in this form of immune dysregulation are not completely understood, although the release of LPS from bacteria and its recognition by host cells are generally thought to be the initial events in the development of sepsis, thus triggering the inflammatory reaction that may subsequently resu…”
BackgroundResultInfluentialKruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 1×
“In the latter, it is particularly used for maintenance therapy in patients with ulcerative colitis in remission, showing an equivalent efficacy to the standard drug mesalazine, used in this condition (Kruis et al., 2004).”
BackgroundProbiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482 · cited 1×
“Furthermore, this probiotic strain may reinforce the mucosal barrier and restore it when it is disrupted, specifically through the up-regulation of expression of the mRNA for the zonula occludens proteins ZO-1 and ZO-2 in intestinal epithelial cells (Ukena et al., 2007; Zyrek et al., 2007).”
BackgroundClinical use of E. coli Nissle 1917 in inflammatory bowel disease
Schultz, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20377 · Cited by 310 · cited 9×
“, 2008), diverticulitis (Fric and Zavoral, 2003) and IBD (Schultz, 2008).”
BackgroundInfluentialLactobacillus GG Bacteria Ameliorate Arthritis in Lewis Rats
Baharav, E., Weinberger, A., Mor, F., & Halpern, M. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.8.1964 · Cited by 144
Cited by
How to select a probiotic? A review and update of methods and criteria
de Melo Pereira, G. V., de Oliveira Coelho, B., Magalhães Júnior, A. I., Thomaz-Soccol, V., & Soccol, C. R. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.09.003 · Cited by 523
Fábrega, M.-J., Rodríguez-Nogales, A., Garrido-Mesa, J., Algieri, F., Badía, J., Giménez, R., Gálvez, J., & Baldomà, L. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01274 · Cited by 240
“The OMV-mediated anti-inflammatory effect was clearly associated with an improvement in the altered immune response accompanying DSS-induced colonic damage, thus mimicking the immunomodulatory properties described for this probiotic both in vivo and in vitro (Kruis et al., 2004; Grabig et al., 2006; Arribas et al., 20…”
BackgroundSelf-citationThe non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic
Sonnenborn, U., & Schulze, J. (2009) · Microbial Ecology in Health and Disease · doi:10.3109/08910600903444267 · Cited by 232
Lin, T.-L., Shu, C.-C., Chen, Y.-M., Lu, J.-J., Wu, T.-S., Lai, W.-F., Tzeng, C.-M., Lai, H.-C., & Lu, C.-C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00554 · Cited by 143
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138
Metadata
- Authors
- Arribas, B., Rodríguez‐Cabezas, M., Camuesco, D., Comalada, M., Bailón, E., Utrilla, P., Nieto, A., Concha, A., Zarzuelo, A., & Gálvez, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-07
- Volume
- 157
- Issue
- 6
- Pages
- 1024-1033
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2045075190
- Cited by
- 73
- References
- 5
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti‐inflammatory effects in lipopolysaccharide‐induced sepsis in mice. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00270.x
- The paper
- Arribas, B., Rodríguez‐Cabezas, M., Camuesco, D., Comalada, M., Bailón, E., Utrilla, P., Nieto, A., Concha, A., Zarzuelo, A., & Gálvez, J. (2009). A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti‐inflammatory effects in lipopolysaccharide‐induced sepsis in mice. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00270.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.